Werewolf Therapeutics is a biopharmaceutical company, engaged in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Co. is utilizing its proprietary PREDATOR platform to design molecules that stimulate both adaptive and innate immunity with the aim of addressing the limitations of conventional proinflammatory immune therapies. Co.'s molecules, which it refers to as INDUKINE molecules, are intended to activate selectively in the tumor microenvironment. Co.'s product candidates, WTX-124 and WTX-330, are delivered, activated Interleukin-2 and Interleukin-12, respectively, INDUKINE molecules for the treatment of solid tumors. The HOWL YTD return is shown above.
The YTD Return on the HOWL YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether HOWL YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the HOWL YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|